DOI QR코드

DOI QR Code

Prognostic Role of Hepatoma-derived Growth Factor in Solid Tumors of Eastern Asia: a Systematic Review and Meta-Analysis

  • Bao, Ci-Hang (Department of Radiation Oncology, Qilu Hospital of Shandong University) ;
  • Liu, Kun (Center for Health Management and Policy, Key Lab of Health Economics and Policy, Ministry of Health, Shandong University) ;
  • Wang, Xin-Tong (Department of Radiation Oncology, Qilu Hospital of Shandong University) ;
  • Ma, Wei (Department of Radiation Oncology, Cancer Hospital, General Hospital of Ningxia Medical University) ;
  • Wang, Jian-Bo (Department of Radiation Oncology, Qilu Hospital of Shandong University) ;
  • Wang, Cong (Department of Radiation Oncology, Qilu Hospital of Shandong University) ;
  • Jia, Yi-Bin (Department of Radiation Oncology, Qilu Hospital of Shandong University) ;
  • Wang, Na-Na (Department of Radiation Oncology, Qilu Hospital of Shandong University) ;
  • Tan, Bing-Xu (Department of Radiation Oncology, Qilu Hospital of Shandong University) ;
  • Song, Qing-Xu (Department of Radiation Oncology, Qilu Hospital of Shandong University) ;
  • Cheng, Yu-Feng (Department of Radiation Oncology, Qilu Hospital of Shandong University)
  • Published : 2015.03.18

Abstract

Hepatoma-derived growth factor (HDGF) is a novel jack-of-all-trades in cancer. Here we quantify the prognostic impact of this biomarker and assess how consistent is its expression in solid tumors. A comprehensive search strategy was used to search relevant literature updated on October 3, 2014 in PubMed, EMBASE and WEB of Science. Correlations between HDGF expression and clinicopathological features or cancer prognosis was analyzed. All pooled HRs or ORs were derived from random-effects models. Twenty-six studies, primarily in Eastern Asia, covering 2,803 patients were included in the analysis, all of them published during the past decade. We found that HDGF overexpression was significantly associated with overall survival (OS) ($HR_{OS}=2.35$, 95%CI=2.04-2.71, p<0.001) and disease free survival (DFS) ($HR_{DFS}=2.25$, 95%CI =1.81-2.79, p<0.001) in solid tumors, especially in non-small cell lung cancer, hepatocellular carcinoma and cholangiocarcinoma (CCA). Moreover, multivariate survival analysis showed that HDGF overexpression was an independent predictor of poor prognosis ($HR_{OS}=2.41$, 95%CI: 2.02-2.81, p<0.001; $HR_{DFS}=2.39$, 95%CI: 1.77-3.24, p<0.001). In addition, HDGF overexpression was significantly associated with tumor category (T3-4 versus T1-2, OR=2.12, 95%CI: 1.17-3.83, p=0.013) and lymph node status (N+ versus N-, OR=2.37, 95%CI: 1.31-4.29, p=0.03) in CCA. This study provides a comprehensive examination of the literature available on the association of HDGF overexpression with OS, DFS and some clinicopathological features in solid tumors. Meta-analysis results provide evidence that HDGF may be a new indicator of poor cancer prognosis. Considering the limitations of the eligible studies, other large-scale prospective trials must be conducted to clarify the prognostic value of HDGF in predicting cancer survival.

Keywords

HDGF;prognosis;clinicopathological features;solid tumors;meta-analysis

References

  1. Bao C, Wang J, Ma W, et al (2014). HDGF: a novel jack-of-alltrades in cancer. Future Oncol, 10, 2675-85. https://doi.org/10.2217/fon.14.194
  2. Cao Z, Bao M, Miele L, et al (2013). Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer, 49, 3914-23. https://doi.org/10.1016/j.ejca.2013.07.148
  3. Chang KC, Tai MH, Lin JW, et al (2007). Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer, 121, 1059-65. https://doi.org/10.1002/ijc.22803
  4. Chen B, Huang T, Jiang J, et al (2014). miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. Mol Cell Biochem, 388, 211-8. https://doi.org/10.1007/s11010-013-1912-3
  5. Chen SC, Kung ML, Hu TH, et al (2012a). Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial-mesenchymal transition. J Pathol, 228, 158-69. https://doi.org/10.1002/path.3988
  6. Chen X, Yun J, Fei F, et al (2012b). Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer. Pathol Res Pract, 208, 437-43. https://doi.org/10.1016/j.prp.2012.03.004
  7. Deeks JJ, Higgins JPT, Altman DG (2011). Chapter 9: analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0. [Online]. the cochrane collaboration. http://www.cochrane-handbook.org/.
  8. Duval S, Tweedie R (2000). Trim and fill: A simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455-63. https://doi.org/10.1111/j.0006-341X.2000.00455.x
  9. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  10. Guo H, Li W, Zheng T, et al (2014a). MiR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumour Biol, 35, 8861-6. https://doi.org/10.1007/s13277-014-2153-0
  11. Guo S, Liu HD, Liu YF, et al (2014b). Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma. Tumour Biol, 36, 353-64
  12. Guo Z, He Y, Wang S, et al (2011). Various effects of hepatomaderived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol Rep, 26, 511-7.
  13. Han Y, Zhang W, Liu Y (2013). Identification of hepatomaderived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma. World J Surg, 37, 2419-27. https://doi.org/10.1007/s00268-013-2132-4
  14. Hanada S, Kakehashi A, Nishiyama N, et al (2013). Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma. Cancer Biomark, 13, 289-98.
  15. Hanahan D (2014). Rethinking the war on cancer. Lancet, 383, 558-63. https://doi.org/10.1016/S0140-6736(13)62226-6
  16. Hayes DF, Isaacs C, Stearns V (2001). Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia, 6, 375-92. https://doi.org/10.1023/A:1014778713034
  17. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  18. Hsu SS, Chen CH, Liu GS, et al (2012). Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J Neurooncol, 107, 101-9. https://doi.org/10.1007/s11060-011-0733-z
  19. Hu TH, Huang CC, Liu LF, et al (2003). Expression of hepatomaderived growth factor in hepatocellular carcinoma. Cancer, 98, 1444-56. https://doi.org/10.1002/cncr.11653
  20. Hu TH, Lin JW, Chen HH, et al (2009). The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum, 52, 319-26. https://doi.org/10.1007/DCR.0b013e31819d1666
  21. Iwasaki T, Nakagawa K, Nakamura H, et al (2005). Hepatomaderived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep, 13, 1075-80.
  22. Li D, Han Z, Liu J, et al (2013a). Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67. Med Oncol, 30, 702. https://doi.org/10.1007/s12032-013-0702-9
  23. Li M, Shen J, Wu X, et al (2013b). Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion. Med Oncol, 30, 587. https://doi.org/10.1007/s12032-013-0587-7
  24. Li SZ, Zhao YB, Cao WD, et al (2013c). The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome. Med Oncol, 30, 622. https://doi.org/10.1007/s12032-013-0622-8
  25. Lin YW, Li CF, Chen HY, et al (2012). The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol, 48, 629-35. https://doi.org/10.1016/j.oraloncology.2012.01.014
  26. Liu YF, Zhao R, Guo S, et al (2011). Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann Surg Oncol, 18, 872-9. https://doi.org/10.1245/s10434-010-1303-x
  27. Mao J, Xu Z, Fang Y, et al (2008). Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci, 99, 2120-7. https://doi.org/10.1111/j.1349-7006.2008.00928.x
  28. Natrajan R, Williams RD, Hing SN, et al (2006). Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol, 210, 49-58. https://doi.org/10.1002/path.2021
  29. Ordonez-Moran P, Huelsken J (2014). Complex metastatic niches: already a target for therapy? Curr Opin Cell Biol, 31, 29-38. https://doi.org/10.1016/j.ceb.2014.06.012
  30. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  31. Ren H, Chu Z, Mao L (2009). Antibodies targeting hepatomaderived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther, 8, 1106-12. https://doi.org/10.1158/1535-7163.MCT-08-0779
  32. Ren H, Tang X, Lee JJ, et al (2004). Expression of hepatomaderived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol, 22, 3230-7. https://doi.org/10.1200/JCO.2004.02.080
  33. Savola S, Klami A, Tripathi A, et al (2009). Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer, 9, 17. https://doi.org/10.1186/1471-2407-9-17
  34. Song Y, Hu Z, Long H, et al (2014). A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma. J Neurooncol, 119, 285-95. https://doi.org/10.1007/s11060-014-1512-4
  35. Tao F, Ye MF, Sun AJ, et al (2014). Prognostic significance of nuclear hepatoma-derived growth factor expression in gallbladder cancer. World J Gastroenterol, 20, 9564-9.
  36. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  37. Tsai HE, Liu GS, Kung ML, et al (2013). Downregulation of hepatoma-derived growth factor contributes to retarded lung metastasis via inhibition of epithelial-mesenchymal transition by systemic POMC gene delivery in melanoma. Mol Cancer Ther, 12, 1016-25. https://doi.org/10.1158/1535-7163.MCT-12-0832
  38. Uyama H, Tomita Y, Nakamura H, et al (2006). Hepatomaderived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res, 12, 6043-8. https://doi.org/10.1158/1078-0432.CCR-06-1064
  39. Wang L, Jiang Q, Hua S, et al (2014). High nuclear expression of HDGF correlates with disease progression and poor prognosis in human endometrial carcinoma. Dis Markers, 2014, 298795.
  40. Wang S, Fang W (2011). Increased expression of hepatomaderived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma. Histopathology, 58, 217-24. https://doi.org/10.1111/j.1365-2559.2010.03739.x
  41. Wells GA, Shea B, O'Connell D, et al (2012). The newcastleottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Online]. ottawa health research institute web site. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  42. Woodward M (2014). A consensus plan for action to improve access to cancer care in the association of Southeast Asian nations (ASEAN) region. Asian Pac J Cancer Prev, 15, 8521-6. https://doi.org/10.7314/APJCP.2014.15.19.8521
  43. Yamamoto S, Tomita Y, Hoshida Y, et al (2007). Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol, 14, 2141-9. https://doi.org/10.1245/s10434-007-9369-9
  44. Yamamoto S, Tomita Y, Hoshida Y, et al (2006). Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res, 12, 117-22. https://doi.org/10.1158/1078-0432.CCR-05-1347
  45. Yang Y, Li H, Zhang F, et al (2013). Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma. J Pathol, 231, 323-34. https://doi.org/10.1002/path.4241
  46. Yang Y, Zhen T, Zhang F, et al (2014). p53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour. J Clin Pathol, 67, 235-42. https://doi.org/10.1136/jclinpath-2013-201705
  47. Ye F, Cheng Q, Zhou C, et al (2011). Hepatoma-derived growth factor is a novel prognostic factor for cervical squamous cell carcinoma. Histopathology, 58, 982-4. https://doi.org/10.1111/j.1365-2559.2011.03839.x
  48. Yoshida K, Tomita Y, Okuda Y, et al (2006). Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol, 13, 159-67. https://doi.org/10.1245/ASO.2006.11.035
  49. Zhang A, Long W, Guo Z, et al (2010). Development and clinical evaluation of a multi-purpose mAb and a sandwich ELISA test for hepatoma-derived growth factor in lung cancer patients. J Immunol Methods, 355, 61-7. https://doi.org/10.1016/j.jim.2010.02.011
  50. Zhang J, Chen N, Qi J, et al (2014). HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer. J Cancer Res Clin Oncol, 140, 1441-9. https://doi.org/10.1007/s00432-014-1687-2
  51. Zhang J, Qi J, Guo Y, et al (2011). Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer. Chinese J Lung Cancer, 14, 211-8.
  52. Zhao J, Yu H, Lin L, et al (2011). Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF). J Proteomics, 75, 588-602. https://doi.org/10.1016/j.jprot.2011.08.021
  53. Zhou NX, Zhou YY, Huo JR (2010a). Significance of HDGF expression in hepatocellular carcinoma tissue and HepG2 cells. World Chinese J Digestol, 18, 2427-33.
  54. Zhou S, Xu S, Zhang H, et al (2007a). Expression of hepatomaderived growth factor and its clinical implication in stage I non-small cell lung cancer. Chinese J Lung Cancer, 10, 291-5.
  55. Zhou S, Xu S, Zhang H, et al (2007a). Expression of hepatomaderived growth factor and its clinical implication in stage I non-small cell lung cancer. Chinese J Lung Cancer, 10, 291-5.
  56. Zhou Y, Zhou N, Fang W, et al (2010b). Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol, 5, 58. https://doi.org/10.1186/1746-1596-5-58

Cited by

  1. Hepatoma-Derived Growth Factor: Its Possible Involvement in the Progression of Hepatocellular Carcinoma vol.16, pp.12, 2015, https://doi.org/10.3390/ijms160614086